Alykomed Global Solutions LLC United States

Alykomed Global Solutions LLC (AGSL), based in New York, is a respected and established provider of strategic personalized corporate solutions to the Biopharma industry. Our clients embody a wide range of companies, from innovative startups to larger established, public companies. Our projects include global business development, financial, investment, and capital support, and scientific based endeavors, among others. We are committed to our clients’ long term success, optimized growth strategies, and profitability potential.

We proudly apply our deep scientific knowledge, and combine this with our strong corporate and business development experience and an extensive scientific/business network. Our established and trusted financial investment banking service/registered broker partner, provides our clients with targeted capital and financial solutions and extensive access to institutional and retail investors. These capital services cover a wide range of investment opportunities and offerings, including, but not limited to IPOs and securities offerings, private placements, mergers and acquisition, bank and debt financing etc.

We also undertake strategic growth initiatives through global business development, researching scientific and drug development platforms, assisting with internal valuations, or assistance with other projects- we offer knowledge, experience, leadership, global awareness, and creativity. We work with a global network of professionals, having done business in North America, UK/Europe, and Asia, especially within the United States, Japan, South Korea, and China.
Headquartner in China
Plan in China
Our current objectives are two-fold- *Meeting with companies that would benefit from our strategic consulting and financing services. *Meeting with investors and business development executives on behalf of current clients- -Company 1: Pre-clinical- Non-opioid, small molecules for neuropathic pain and epilepsy. Safety profiles and efficacy results better or equal to Pregabalin. -Company 2: Pre-clinical- Sepsis drug which, when co-administered with low dose corticosteroids dramatically improves survival. Seeking to fast track for COVID-19. -Company 3: Entering Phase II trials- ATP enhancing drugs for CNS indications, Mitochondrial Disease, Parkinson's, COVID-19 -Company 4.: Japan-based: Clinical telemedicine services for Japanese expats living overseas
Scott Kahn
Founder 
Functionality

Aposave United Kingdom

Aposave is the global pharmaceutical and healthcare services division of the Abacus Medicine Group.

The company mission is to assist patients with unmet medical needs get access to innovative new medicines, while assisting the manufacturers to maximise the clinical and commercial potential of their assets.

Our promise to healthcare and pharmaceutical customers is to provide a new generation of healthcare and pharmaceutical services to support their new generation of pharmaceutical products throughout the 2020’s and beyond.

To do this Aposave has developed a market leading range of services focused on providing access to medicines around the world. Working across the lifecycle in partnership with pharmaceutical and biotechnology companies Aposave creates and delivers innovative solutions that ensure patients can get timely access to the medicines they need, whilst helping pharmaceutical and biotechnology companies achieve their clinical and commercial objectives.
Aposave has a range of services to support the efficient running of clinical trials called Clinical Trial Solutions (CTS). This is an area where there are great synergies with our parent company, Abacus Medicine. The Abacus Medicine Group holds over 4500 marketing authorisations, and this provides Aposave with unrivalled access to the medicines required to support the running of clinical trials. In addition, Aposave has developed some unique approaches to minimising wastage of products that have expired or are no longer required for a trial.
Aposave has extensive knowledge and experience in managing the distribution of specialty medicines, and this service line is called Specialty Commercial Distribution (SCD). Higher value, lower volume specialty medicines often do not sit well with the traditional distribution model, and this is where our team of experts develop innovative solutions to help ensure patients have access, while maintaining the commercial requirements of our clients.
Aposave is a strategic partner to the pharmaceutical and biotech industry. Aposave Access Programs (AAP) provide a framework for a partnership where Aposave creates, implements, and manages a program on behalf of a drug manufacturer to provide access to their drug in countries where it is not commercially available. This can be either in the prelaunch, or the post launch stage of the product lifecycle. Each program is designed to meet the specific needs of the manufacturer.
The final service that Aposave provides is very much focussed on the patient, and as such is called Individual Access Requests (IAR). Patients with an unmet medical need often require access to a medicine that is not commercially available in the country where they live. When the customer service team at Aposave receive such a request from a healthcare professional, if we do not already have the product in stock, we find a source of the product and ensure we deliver it, in compliance with appropriate regulations, to the relevant medical establishment ready for the patient to receive treatment.
Website:
www.aposave.com
Company Size (Fulltime employees)
Year of foundation
2013
Funding Status
N/A
Headquartner in China
Plan in China
We currently have an office in Hong Kong that supports the AsiaPacific region and are planning a strategic initiative that will see the first Aposave office in Mainland China. This will allow us to increase the support we provide the rapidly expanding pharmaceutical industry in this country.
Mr William Van
LinkedIn logo Marketing Manager 
Mr Charleston Chiu
LinkedIn logo Sales Manager 
Functionality

Bioprogress Switzerland

Who We Are

An executive search and talent acquisition specialist with a wealth of experience in the life science business sector
An alternative to the generalist search firms that offer only general search services
Able to find the right talent for you with the right approach and understanding the complexity of the life science industry
Able to build pools helping our clients to attract a long term and sustainable talent pipeline for current and future requirements, placing your company ahead of competition
Company Size (Fulltime employees)
Year of foundation
1997
Headquartner in China
Plan in China
We have an office in HK,Shanghai and BKK
Jacob Hoekstra
CEO 
Functionality
Sam Meredith
Vice President 
Functionality

Cerevel Therapeutics United States

Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.

We seek to transform the lives of people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia, through the development of novel therapies. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with the proven expertise of pharmaceutical company drug discovery and development.
Company Size (Fulltime employees)
Year of foundation
2018
Stock Market and Ticker/Symbol/Number
NASDAQ: CERE
Please specify your partnering goal
Interested in better understanding the current CNS biopharma landscape in China
Headquartner in China
Medtech Development Stage
Scott Lewis
Corporate Development & Strategy 
Functionality

Consulate General of Canada in Shanghai China

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.
Lulu Mi
Life Sciences Trade Commissioner 
Functionality
Dr Kshitij Soni
LinkedIn logo CEO 
Functionality

Global Clinical Trials (GCT) United States

Global Clinical Trials (GCT) is a premium contract-research organization (CRO) that offers support for the clinical Phase I-IV studies as well as post-marketing activities to Big Pharma, small and medium-sized biotech enterprises, groups and funds, as well as large universities and institutions. Headquartered in Princeton, USA, GCT offers both local and global support through 10 own operational offices in Bulgaria, Czech Republic, Georgia, Hungary, India, Kazakhstan, Latvia, Lithuania, Estonia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine.
GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Our monitors and project managers are all certified clinicians experienced in GCP clinical research. Our experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines.
GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients.
Since 2006 GCT is also an Exclusive Partner of “The White Nights” International ophthalmology congress in Russia.
Company Size (Fulltime employees)
Year of foundation
2001
Stock Market and Ticker/Symbol/Number
N/A
Please specify your partnering goal
Networking, new business opportunities
Headquartner in China
Plan in China
GCT is looking for potential new business opportunities, offering full-service clinical trials support worldwide for Chinese pharma companies.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Development Stage
Your Service Name
clinical trials, market authorization, registration, consulting
Service Description
logistics, regulatory services, project and site management, pharmacovigilance, medical monitoring, data management, biostatistics, medical writing, GDPR and DPO, EU Legal representation,
Target Client Type
Pharma, Biotech, Device companies
Aleksandr Stiblo
LinkedIn logo Director, Business Development 
Functionality

Hong Kong Biotechnology Organization China

Hong Kong Biotechnology Organization is an independent nonprofit organization (Charities exempted from tax under Section 88 of the Inland Revenue Ordinance) with the goal to promote best practice, raise awareness across the biotechnology industry while providing added value benefits to its members, whether they are students, researchers, entrepreneurs, industry bodies, public or private sector representatives.

Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.
Company Size (Fulltime employees)
Year of foundation
2010
Funding Status
Seeking for sponsorship or partnership for BIOHK2021
Headquartner in China
Chris Chow
Sales Manager 
Functionality

IHM-GBA China

Based in Guanghzou, China, IHM-GBA is an innovation center focusing on high performance medical device. We are seeking global opportunities of bringing disruptive technologies to the Chinese market. We invest in and partner with startups that are interested in exploring China and use our resources to commercialize their products.

Website:
www.ihm-gba.com
Year of foundation
2019
Please specify your partnering goal
investment/partnership/license
Headquartner in China
Investment Focus
Medical device
Mr shu zeng
Director 
Functionality

INOVOTION France

INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to oncology and immuno-oncology efficacy studies and early toxicity evaluations.
Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage.
This breaking-thought technology, based on chick embryo, provides early analysis of your anti-cancer treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs.
It’s rapid Go/No Go decision with multi-cancer screening capacities.
This next generation of in vivo efficacy and toxicity tests covers fours main aspects:
- EFFICACY assays for your treatments in oncology and immuno-oncology
- EARLY TOXICITY assays for your drug candidates
- TARGET VALIDATION in oncology
- MULTI-CANCER SCREENING to (re)positioning your treatment
Company Size (Fulltime employees)
Year of foundation
2015
Headquartner in China
Plan in China
At this step, We want to understand the Chinese Market and we are looking for our first Chinese Customers and/or Partners
Philippe Fornies
Head of Business Development 
Functionality